Literature DB >> 61496

Amine metabolism and the small bowel in uraemia.

M L Simenhoff, J J Saukkonen, J F Burke, L G Wesson, R W Schaedler.   

Abstract

Intestinal intubation was carried out in 21 subjects: 9 with end-stage renal failure, 2 with early renal insufficiency, 7 untreated patients with blind-loop syndrome, and 3 normal volunteers. All 9 patients with uraemia had significantly raised duodenal dimethylamine (D.M.A.) concentrations compared with the other groups tested. Alteration of the intestinal bacterial flora with antibiotics markedly reduced serum D.M.A. and trimethylamine concentrations and modified the symptoms. Potentially toxic metabolites in the small bowel might have significant nutritional and toxic sequelae in uraemia and these findings suggest that current therapeutic approaches to the treatment of end-stage kidney disease should be re-examined in relation to bowel flora.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 61496     DOI: 10.1016/s0140-6736(76)91207-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  10 in total

Review 1.  The Gut as a Source of Inflammation in Chronic Kidney Disease.

Authors:  Wei Ling Lau; Kamyar Kalantar-Zadeh; Nosratola D Vaziri
Journal:  Nephron       Date:  2015-05-09       Impact factor: 2.847

2.  Associations of Trimethylamine N-Oxide With Nutritional and Inflammatory Biomarkers and Cardiovascular Outcomes in Patients New to Dialysis.

Authors:  George A Kaysen; Kirsten L Johansen; Glenn M Chertow; Lorien S Dalrymple; John Kornak; Barbara Grimes; Tjien Dwyer; Alexander W Chassy; Oliver Fiehn
Journal:  J Ren Nutr       Date:  2015-03-19       Impact factor: 3.655

3.  In vitro metabolism of creatinine, methylamine and amino acids by intestinal contents of normal and uraemic subjects.

Authors:  C W Owens; Z P Albuquerque; G M Tomlinson
Journal:  Gut       Date:  1979-07       Impact factor: 23.059

4.  Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.

Authors:  W H Wilson Tang; Zeneng Wang; Bruce S Levison; Robert A Koeth; Earl B Britt; Xiaoming Fu; Yuping Wu; Stanley L Hazen
Journal:  N Engl J Med       Date:  2013-04-25       Impact factor: 91.245

5.  Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure.

Authors:  M Magnusson; K E Magnusson; T Sundqvist; T Denneberg
Journal:  Gut       Date:  1991-07       Impact factor: 23.059

Review 6.  Contributory Role of Gut Microbiota and Their Metabolites Toward Cardiovascular Complications in Chronic Kidney Disease.

Authors:  Daniel Y Li; W H Wilson Tang
Journal:  Semin Nephrol       Date:  2018-03       Impact factor: 5.299

7.  Effect of egg ingestion on trimethylamine-N-oxide production in humans: a randomized, controlled, dose-response study.

Authors:  Carolyn A Miller; Karen D Corbin; Kerry-Ann da Costa; Shucha Zhang; Xueqing Zhao; Joseph A Galanko; Tondra Blevins; Brian J Bennett; Annalouise O'Connor; Steven H Zeisel
Journal:  Am J Clin Nutr       Date:  2014-06-18       Impact factor: 7.045

8.  Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease.

Authors:  Nilaksh Gupta; Jennifer A Buffa; Adam B Roberts; Naseer Sangwan; Sarah M Skye; Lin Li; Karen J Ho; John Varga; Joseph A DiDonato; W H Wilson Tang; Stanley L Hazen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-03-26       Impact factor: 8.311

9.  The consequences of altered microbiota in immune-related chronic kidney disease.

Authors:  Wei Ling Lau; Yongen Chang; Nosratola D Vaziri
Journal:  Nephrol Dial Transplant       Date:  2021-09-27       Impact factor: 5.992

Review 10.  Trimethylamine and Trimethylamine N-Oxide, a Flavin-Containing Monooxygenase 3 (FMO3)-Mediated Host-Microbiome Metabolic Axis Implicated in Health and Disease.

Authors:  Diede Fennema; Ian R Phillips; Elizabeth A Shephard
Journal:  Drug Metab Dispos       Date:  2016-05-17       Impact factor: 3.922

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.